https://scholars.lib.ntu.edu.tw/handle/123456789/624363
標題: | Hepatitis C microelimination among people living with HIV in Taiwan | 作者: | Chen, Guan-Jhou Ho, Shu-Yuan Su, Li-Hsin SUI-YUAN CHANG SZU-MIN HSIEH WANG-HUEI SHENG WANG-DA LIU YU-SHAN HUANG KUAN-YIN LIN YI-TING CHEN Su, Yi-Ching Liu, Wen-Chun HSIN-YUN SUN CHIEN-CHING HUNG |
關鍵字: | Men who have sex with men; direct-acting antiviral; injection drug use; sexually transmitted disease; sustained virologic response | 公開日期: | 十二月-2022 | 出版社: | TAYLOR & FRANCIS LTD | 卷: | 11 | 期: | 1 | 起(迄)頁: | 1664 | 來源出版物: | Emerging microbes & infections | 摘要: | To reach the WHO target of hepatitis C virus (HCV) elimination by 2025, Taiwan started to implement free-of-charge direct-acting antiviral (DAA) treatment programme in 2017. Evaluating the progress of HCV microelimination among people living with HIV (PLWH) is a critical step to identify the barriers to HCV elimination. PLWH seeking care at a major hospital designated for HIV care in Taiwan between January 2011 and December 2021 were retrospectively included. For PLWH with HCV-seropositive or HCV seroconversion during the study period, serial HCV RNA testing was performed using archived samples to confirm the presence of HCV viremia and estimate the prevalence and incidence of HCV viremia. Overall, 4199 PLWH contributed to a total of 27,258.75 person-years of follow-up (PYFU). With the reimbursement of DAAs and improvement of access to treatments, the prevalence of HCV viremia has declined from its peak of 6.21% (95% CI, 5.39-7.12%) in 2018 to 2.09% (95% CI, 1.60-2.77%) in 2021 (decline by 66.4% [95% CI, 55.4-74.7%]); the incidence has declined from 25.94 per 1000 PYFU (95% CI, 20.44-32.47) in 2019 to 12.15% per 1000 PYFU (95% CI, 8.14-17.44) (decline by 53.2% [95% CI, 27.3-70.6%]). However, the proportion of HCV reinfections continued to increase and accounted for 82.8% of incident HCV infections in 2021. We observed significant declines of HCV viremia among PLWH with the expansion of the DAA treatment programme in Taiwan. Further improvement of the access to DAA retreatments is warranted to achieve the goal of HCV microelimination. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/624363 | ISSN: | 2222-1751 | DOI: | 10.1080/22221751.2022.2081620 |
顯示於: | 醫學院附設醫院 (臺大醫院) |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。